SCHEMBL6477906

SCHEMBL6477906

CC(C)(C)OC(=O)N[C@H](C1CCCCCCC1)[C@H](O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 5/20 0.44
CTSS P25774 3/20 0.44
GAA P10253 2/20 0.43
EPHX1 P07099 2/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
BTK Q06187 1/20 0.41
KMT2A Q03164 2/20 0.38
AAK1 Q2M2I8 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CACNA1B Q00975 1/20 0.35
CYP2D6 P10635 1/20 0.35
CTSL P07711 2/20 0.35
CTSB P07858 1/20 0.35
MEN1 O00255 1/20 0.35
KDM1A O60341 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5848683 0.98 CTSK (0.42) CTSKCTSSGAAEPHX1HDAC4
SCHEMBL8286493 0.95 BTK (0.46) CTSKCTSSGAAEPHX1HDAC4
SCHEMBL8554341 0.92 CTSK (0.41) CTSKCTSSGAABTKKMT2A
SCHEMBL14011490 0.83 GAA (0.47) CTSKCTSSGAAEPHX1HDAC4
SCHEMBL8279336 0.82 BTK (0.41) CTSKCTSSGAAEPHX1HDAC4
SCHEMBL8288558 0.82 BTK (0.41) CTSKCTSSGAAEPHX1HDAC4
SCHEMBL23005710 0.80 CTSS (0.47) CTSKCTSSGAAEPHX1HDAC4
SCHEMBL22285128 0.80 CTSS (0.47) CTSKCTSSGAAEPHX1HDAC4
SCHEMBL22285129 0.80 CTSS (0.47) CTSKCTSSGAAEPHX1HDAC4
SCHEMBL22125910 0.80 CTSS (0.47) CTSKCTSSGAAEPHX1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 US disclosed
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP CTSK 2334/4885CTSS 1777/4885GAA 2028/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP CTSK 2334/4885CTSS 1777/4885GAA 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.